Stockreport
Biogen: Why I Anticipate A Difficult 2026 For 'End Of An Era' Pharma [Seeking Alpha]
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
MS franchise erosion accelerates with patent expiries and generic Tysabri, while new products and pipeline assets lack clear blockbuster potential. Leqembi and other recent launches underperform versus expectations, and 2026 guidance is likely to reflect further revenue and EPS declines. Despite low valuation multiples, BIIB's weak pipeline, shrinking revenues, and management's focus on cost-cutting limit upside. Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » Veronique D/iStock Editorial via Getty Images Investment Overview When I last covered Biogen Inc. ( BIIB ), the Cambridge, Massachusetts based pharma and central nervous system ("CNS") disease specialist, in a note for Seeking Alpha last February, I awarded its More on my IG service If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and under
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BIIB | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BIIB alerts
BIIB alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
NEWS
NEWS
- Biogen (NASDAQ:BIIB) had its price target raised by analysts at Mizuho from $177.00 to $207.00. They now have an "outperform" rating on the stock.[MarketBeat]
- Biogen (NASDAQ:BIIB) had its price target raised by analysts at Sanford C. Bernstein from $157.00 to $197.00. They now have a "market perform" rating on the stock.[MarketBeat]
- Biogen (NASDAQ:BIIB) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.[MarketBeat]
- Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy[GlobeNewswire]
- Here's What Analysts Think About Biogen Inc. (BIIB) [Yahoo! Finance][Yahoo! Finance]
- More
BIIB
SEC Filings
SEC Filings
- 1/14/26 - Form 8-K
- 12/3/25 - Form 4
- 11/13/25 - Form SCHEDULE
- BIIB's page on the SEC website
- More